Immunomodulation by colchicine is a well-established therapy for targeting inflammatory pathways in gout, pericarditis and Behchet's disease. In more recent times, evidence has emerged demonstrating a potential role for colchicine in several cardiac conditions. This article aims to summarise the evidence behind the established guidelines for use of low-dose colchicine in pericarditis and examine the evolving evidence for its use in cardiovascular disease and most recently COVID-19.
Keywords: Atherosclerosis; COVID-19; Cardiovascular disease; Colchicine; Pericarditis.
© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.